Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-A1811-based combination therapy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
CTR20230021Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2023; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20230021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230021.